Heron Therapeutics (HRTX) Stock Forecast & Price Target

Heron Therapeutics is supported by a resilient commercial portfolio, with CINVANTI, APONVIE, SUSTOL, and ZYNRELEF giving it multiple revenue streams and reducing reliance on any single product. Despite the CINVANTI patent setback creating a cash-flow overhang, strong clinical results from Exparel reinforce the durability of the post-operative pain market opportunity and support broader adoption in hospitals and outpatient clinics. With 2026 ZYNRELEF execution now the key determinant of recovery from depressed levels, the company still has a credible path to improving fundamentals if it converts product momentum into sustained commercialization.

Heron Therapeutics is facing a deteriorating fundamental profile because the adverse CINVANTI patent ruling threatens the company’s main revenue and cash-flow anchor, which previously funded investment in ZYNRELEF and APONVIE. In 2Q26, total revenue was $37.7M, with CINVANTI at $21.8M, ZYNRELEF at $11.1M and APONVIE at $4.3M, but the company still ended June 30 with only $42.7M of cash against about $142.7M of notes payable and convertible notes. With 2026 guidance withdrawn, debt covenants tightened through 2027, and ZYNRELEF’s ramp still too slow to offset likely CINVANTI erosion, the balance of risk has shifted toward weaker liquidity, reduced financial flexibility, and uncertainty around standalone viability.